Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Drug: Ventolin 90Mcg/Actuation Inhalation Aerosol

Registration Number: NCT04606394

Lead Sponsor: Pulmonary Research Institute of Southeast Michigan

Brief Summary: The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine the testing capabilities of the preferred PIF maneuver and to relate this PIF measurement to meaningful clinical outcomes in COPD patients

Detailed Description: Study Design and Methods Rationale

* The expected FEV1 response to a bronchodilator is uncertain as multiple factors influence this measure, including severity of disease, day to day variability, varying reversibility in COPD patients, the delivery of the drug to a patient and the effectiveness of the medication delivered. Thus, the measurement of an acute bronchodilator response after delivering a long acting bronchodilator may not identify whether a medication has been effectively delivered to a patient.

* However, if a long acting bronchodilator has not been effectively delivered to the lung, then subsequent delivery of a short acting bronchodilator should produce a significant additional bronchodilator response. On the other hand, if a long acting bronchodilator has been effectively delivered to the lung, then subsequent delivery of a short acting bronchodilator should not produce any further significant bronchodilation.

* Based on this rationale, comparison of the acute bronchodilator response to a short acting bronchodilator after receiving a long acting should identify whether drug delivery is ineffective in a selected patient population, irrespective of baseline FEV1 and of any partial response to the long acting bronchodilator. Comparison of the short acting bronchodilator measurement between patient groups with differing PIF thresholds should identify whether PIF has an impact of drug delivery of a long acting bronchodilator via a DPI.

* Open label design comparing the acute bronchodilator response after delivery of a long acting bronchodilator via Ellipta DPI in patients with normal, suboptimal and minimal PIF.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 30

Inclusion Criteria

smoking history >10 pack years
pre-bronchodilator FEV1 <60% predicted
post-bronchodilator FEV1/FVC <70%
female participants are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions applies:
not a woman of childbearing potential OR
agree to follow the contraceptive guidance during the treatment period and until the safety follow-up contact after the last dose of study treatment
stratification requiring at least 1/3 of patients having a PIF of < 60L/min (AM pre-dose based on using the level 2 InCheck Dial resistance setting with a sharp maximal effort starting after exhaling fully)

Exclusion Criteria

any subject with unstable disease, including
COPD exacerbation in the last 6 weeks
upper respiratory tract in in the last 4 weeks
COPD or upper respiratory tract infection during run-in (subjects may be re-screened x 1 when stable after an acute event)
pulmonary disease other than COPD
any lung resection
unstable cardiac conditions (at the discretion of the investigator)
other unstable medical conditions (at the discretion of the investigator)

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open label treatment	Trelegy Ellipta 100/62.5/25Mcg Inh 30D	All subjects receive Trelegy and Ventolin for 2 weeks
Open label treatment	Ventolin 90Mcg/Actuation Inhalation Aerosol	All subjects receive Trelegy and Ventolin for 2 weeks

Primary Outcome Measures

Name	Time	Method
DPI Responder Analysis in Patients With Suboptimal PIF (<60 L/Min)	2 weeks	Outcome = the number of subject test days (2 test days per subject) meeting responder criteria defined as: DPI Responder - a positive (\>50 ml) peak FEV1 response 2 hours after Trelegy Ellipta® DPI with a negative (\<50mL) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy) DPI Partial Responder a positive (\>50 ml) peak FEV1 response 2 hours after Trelegy® Ellipta DPI with a positive (\>50 ml) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy) DPI Failure - a negative (\<50mL) peak FEV1 response 2 hours after Trelegy Ellipta® DPI with a positive (\>50 ml) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy) Irreversible - a negative (\<50mL) peak FEV1 response 2 hours after Trelegy Ellipta® DPI with a negative (\<50mL) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy)

Secondary Outcome Measures

Name	Time	Method
PIF Measurement Techniques	Baseline on day of testing	PIF value (L/min) based on different PIF measurement techniques
DPI Responder Analysis in Patients With Reduced PIF (<45 L/Min)	2 weeks	Outcome = the number of subject test days (2 test days per subject) meeting responder criteria defined as: DPI Responder - a positive (\>50 ml) peak FEV1 response 2 hours after Trelegy Ellipta® DPI with a negative (\<50mL) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy) DPI Partial Responder a positive (\>50 ml) peak FEV1 response 2 hours after Trelegy® Ellipta DPI with a positive (\>50 ml) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy) DPI Failure - a negative (\<50mL) peak FEV1 response 2 hours after Trelegy Ellipta® DPI with a positive (\>50 ml) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy) Irreversible - a negative (\<50mL) peak FEV1 response 2 hours after Trelegy Ellipta® DPI with a negative (\<50mL) peak FEV1 response 30 minutes after Ventolin® pMDI (2.5 hours post Trelegy)